Sign up
Log in
ImmunityBio Posts Upbeat Q4 Earnings, Joins Arcellx, Vanda Pharmaceuticals And Other Big Stocks Moving Higher On Monday
Share
Listen to the news

U.S. stocks were lower, with the Dow Jones index falling around 400 points on Monday.

Shares of ImmunityBio, Inc. (NASDAQ:IBRX) rose sharply on Monday after the company reported better-than-expected quarterly financial results.

ImmunityBio reported quarterly losses of 6 cents per share which beat the analyst consensus estimate of losses of 9 cents per share. The company reported quarterly sales of $38.285 million which beat the analyst consensus estimate of $37.020 million.

ImmunityBio shares jumped 22.2% to $10.63 on Monday.

Here are some other big stocks recording gains in today’s session.

  • Arcellx, Inc. (NASDAQ:ACLX) shares jumped 77.9% to $114.05 after the company announced it will be acquired by Gilead Sciences.
  • Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) gained 55% to $8.96 after the company announced FDA approval for BYSANTI tablets.
  • Enhabit, Inc. (NYSE:EHAB) gained 22.5% to $13.59 after the company announced it will be acquired by Kinderhook Industries.
  • Legend Biotech Corporation (NASDAQ:LEGN) gained 16% to $21.04.
  • Getty Images Holdings, Inc. (NYSE:GETY) surged 13.4% to $0.8400 after the company announced it received clearance from the DOJ for the merger with Shutterstock.
  • Viking Therapeutics, Inc. (NASDAQ:VKTX) rose 12.3% to $34.86.
  • Veris Residential, Inc. (NYSE:VRE) gained 12.1% to $18.80 after the company reported better-than-expected quarterly FFO results and announced it will be acquired by an investor consortium led by Affinius Capital in partnership with Vista Hill Partners.
  • Santacruz Silver Mining Ltd. (NASDAQ:SCZM) rose 10.3% to $12.46.
  • Tidewater Inc. (NYSE:TDW) gained 9.1% to $79.84 after the company announced it acquired Wilson Sons Ultratug Offshore.
  • Moderna, Inc (NASDAQ:MRNA) rose 7.7% to $53.69.
  • Vicor Corporation (NASDAQ:VICR) shares gained 6.8% to $181.69.

Photo via Shutterstock

Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.
What's Trending
No content on the Webull website shall be considered a recommendation or solicitation for the purchase or sale of securities, options or other investment products. All information and data on the website is for reference only and no historical data shall be considered as the basis for judging future trends.